Print | Email Page

Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound

January 2017

Jones Day advised Kowa Company, Ltd. and its subsidiary Kowa Pharmaceuticals America, Inc. in a license agreement with CymaBay Therapeutics for exclusive U.S. rights to Arhalofenate, a compound in late stage clinical development for the treatment of gout.

For additional information about this matter, please contact: Scott Jones

Client(s): Kowa Company, Ltd.
Office(s): Tokyo, Boston, San Diego